|
|
1.
|
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
by Swain, Sandra M.
Published: 2022; ; ; ; Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.; .Department: Associate Dean for Research Development.Publication: Journal Article.Article type: Journal Article.Full author list: Barrios C; Bonnefoi H; Boulet T; De Laurentiis M; Ellis PA; Fehrenbacher L; Gianni L; Gralow J; Harbeck N; Huang CS; Im SA; Im YH; Ito Y; Krop IE; Liu H; Macharia H; Nowecki Z; Shah J; Song C; Swain SM; Toi M; Trask P; Winer EP.UI/PMID: 34890214.Digital Object Identifier: https://dx.doi.org/10.1200/JCO.21.00896 (Click here)
|
|
|
2.
|
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC
by Gallagher, Christopher;
Lynce, Filipa;
Ottaviano, Yvonne.
Published: 2021; ; ; Citation: Clinical Cancer Research. 27(21):5810-5817, 2021 11 01.; .Institution: MedStar Franklin Square Medical Center; Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Althouse SK; Ballinger TJ; Bauchle A; Dong Z; Gallagher C; Liu JY; Lynce F; Masters AR; Miller KD; Ottaviano YL; Perkins SM; Sardesai SD; Schneider BP; Storniolo AM; Stratford RE Jr; Thomas A; Zhang JT.UI/PMID: 34400413.Digital Object Identifier: https://dx.doi.org/10.1158/1078-0432.CCR-21-0493 (Click here)
|
|
|
3.
|
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer
by Blackburn, Matthew J;
Chitalia, Ami;
Dilawari, Asma;
Gallagher, Christopher;
Lynce, Filipa;
Mohebtash, Mahsa;
Tiwari, Shruti R.
Published: 2021; ; ; ; Citation: Cancer. 127(19):3622-3630, 2021 10 01.; .Institution: MedStar Franklin Square Cancer Center at Loch Raven Campus; MedStar Washington Hospital Center; Washington Cancer Institute.Department: Hematology & Oncology Fellowship; Hematology and Oncology.Publication: Journal Article.Article type: Journal Article.Full author list: Abu-Khalaf M; Blackburn MJ; Chitalia A; Dilawari A; Gallagher C; Hahn OM; Isaacs C; Lynce F; Mohebtash M; Pohlmann PR; Shajahan-Haq AN; Tan M; Tiwari SR; Warren R; Wu T; Zhuo R.UI/PMID: 34157782.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1002/cncr.33620 (Click here)
|
|
|
4.
|
Intermittent left bundle branch block and acute heart failure in trastuzumab-induced cardiotoxicity
by Masson, Ravi.
Published: 2020; ; ; Citation: BMJ Case Reports. 13(7), 2020 Jul 28.; .Institution: MedStar Washington Hospital Center.Department: Medicine/Internal Medicine.Publication: Journal Article.Article type: Journal Article.Full author list: Bakhshi H; Haddad TM; Masson R.UI/PMID: 32723779.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1136/bcr-2020-236009 (Click here)
|
|
|
5.
|
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
by Swain, Sandra M.
Published: 2020; ; ; Citation: Clinical Cancer Research. 26(16):4233-4241, 2020 08 15.; .Institution: MedStar Health.Department: Associate Dean for Research Development.Publication: Journal Article.Article type: Journal Article.Full author list: Bandos H; Brauer HA; Geyer CE Jr; Goerlitz DS; Harris BT; Lucas PC; Mamounas EP; Rastogi P; Ren Y; Robidoux A; Swain SM; Tang G; Wolmark N.UI/PMID: 32371537.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1158/1078-0432.CCR-20-0152 (Click here)
|
|
|
6.
|
The Role of Angiotensin-Converting Enzyme Inhibitors and beta-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients. [Review]
by Barac, Ana.
Published: 2020; ; ; Citation: Journal of the American Heart Association. 9(2):e015327, 2020 01 21.; .Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Barac A; Brown SA; Okwuosa TM; Volgman AS.UI/PMID: 31960742.Digital Object Identifier: https://dx.doi.org/10.1161/JAHA.119.015327https://dx.doi.org/10.1161/JAHA.119.015327 (Click here) | (Click here)
|
|
|
7.
|
Trastuzumab-Induced Cardiomyopathy. [Review]
by Barac, Ana;
Gates, Emily.
Published: 2019; Citation: Cardiology Clinics. 37(4):407-418, 2019 Nov..Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article; Review.Full author list: Barac A; Barish R; Gates E.UI/PMID: 31587782.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.ccl.2019.07.005 (Click here)
|
|
|
8.
|
Physician Perspectives on Fertility Preservation Discussions with Premenopausal Breast Cancer Patients: Results from a Multihospital Health Care System
by Bozzuto, Laura M;
Haslinger, Michelle;
Thibodeau, Renee;
Tsiapali, Ekaterini V;
Tung, Shawndeep S.
Published: 2019; ; Citation: Annals of Surgical Oncology. 2019 Jul 24; .Institution: MedStar Washington Hospital Center.Department: Surgery/Plastic Surgery.Publication: Journal Article.Article type: Journal Article.Full author list: Bartholomew AJ; Bozzuto LM; Haslinger M; Masciello MC; Thibodeau R; Tsiapali EV; Tung SS.UI/PMID: 31342399.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1245/s10434-019-07563-w (Click here)
|
|
|
9.
|
Neoadjuvant Chemotherapy and Nipple-Sparing Mastectomy: Timing and Postoperative Complications
by Dervishaj, Ornela A;
Tung, Shawndeep S.
Published: 2019; ; Citation: Annals of Surgical Oncology. 26(9):2768-2772, 2019 Sep.; .Institution: MedStar Washington Hospital Center.Department: Surgery/Plastic Surgery.Publication: Journal Article.Article type: Journal Article.Full author list: Bartholomew AJ; Caragacianu DL; Dervishaj OA; Kerivan LT; Sosin M; Tousimis EA; Tung SS; Willey SC.UI/PMID: 31123933.Digital Object Identifier: https://dx.doi.org/10.1245/s10434-019-07418-4 (Click here)
|
|
|
10.
|
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
by Asch, Federico M;
Barac, Ana;
Cunningham, A;
Gallagher, Christopher;
Hofmeyer, Mark;
Srichai, M B;
Swain, Sandra M.
Published: 2019; Citation: Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun..Institution: MedStar Health ; MedStar Health Research Institute; MedStar Heart & Vascular Institute; Washington Cancer Institute.Department: Associate Dean for Research Development.Publication: Journal Article.Article type: Journal Article.Full author list: Asch FM; Barac A; Cunningham A; Dang C; Gallagher C; Geng X; Herbolsheimer P; Hofmeyer M; Isaacs C; Lynce F; Nunes R; Pohlmann PR; Shajahan-Haq A; Smith KL; Srichai MB; Swain SM; Tan MT; Timothee P; Warren R; Yu AF.UI/PMID: 30852761.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1007/s10549-019-05191-2 (Click here)
|
|
|
11.
|
Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors
by Barac, Ana.
Published: ; ; 2019Citation: Breast Cancer Research & Treatment. 174(3):785-794, 2019 Apr..Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Xu X; Chlebowski RT; Shi J; Barac A; Haque R.UI/PMID: 30659431.Digital Object Identifier: https://dx.doi.org/10.1007/s10549-018-05086-8 (Click here)
|
|
|
12.
|
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
by McCarron, Edward C.
Published: ; 2019; ; Citation: ; Lancet Oncology. 20(1):88-99, 2019 01..Institution: MedStar Franklin Square Medical Center.Publication: Journal Article.Article type: Journal Article.Full author list: Bandos H; Brufsky AM; Chia SK; Dakhil SR; Fehrenbacher L; Geyer CE Jr; Graham ML; Jeong JH; Lembersky BC; Mamounas EP; McCarron EC; Paik S; Rastogi P; Seay TE; Soori GS; Swain SM; Wade JL 3rd; Walshe JM; Wickerham DL; Wolmark N.UI/PMID: 30509771.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/S1470-2045(18)30621-1 (Click here)
|
|
|
13.
|
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials
by Lynce, Filipa;
Blackburn, Matthew J.
Published: ; 2018Citation: Breast Cancer Research & Treatment. 168(1):35-41, 2018 Feb..Institution: Washington Cancer Institute; MedStar Washington Hospital Center.Department: Hematology and Oncology.Publication: Journal Article.Article type: Journal Article.Full author list: Lynce F; Blackburn MJ; Cai L; Wang H; Rubinstein L; Harris P; Isaacs C; Pohlmann PR.UI/PMID: 29119354.Digital Object Identifier: https://dx.doi.org/10.1007/s10549-017-4563-3 (Click here)
|
|
|
14.
|
The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study
by Howard, Barbara V.
Published: 2018Citation: ; Breast Cancer Research & Treatment. 167(3):741-749, 2018 02..Institution: MedStar Health Research Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Bock CH; Jay AM; Dyson G; Beebe-Dimmer JL; Cote ML; Hou L; Howard BV; Desai P; Purrington K; Prentice R; Simon MS.UI/PMID: 29063981.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1007/s10549-017-4521-0 (Click here)
|
|
|
15.
|
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
by Swain, Sandra M;
Zapas, John L.
Published: 2017Citation: Journal of Clinical Oncology. 35(35):3942-3948, 2017 Dec 10.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Ganz PA; Romond EH; Cecchini RS; Rastogi P; Geyer CE Jr; Swain SM; Jeong JH; Fehrenbacher L; Gross HM; Brufsky AM; Flynn PJ; Wahl TA; Seay TE; Wade JL 3rd; Biggs DD; Atkins JN; Polikoff J; Zapas JL; Mamounas EP; Wolmark N.UI/PMID: 29072977.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1200/JCO.2017.74.1165 (Click here)
|
|
|
16.
|
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30
by Swain, Sandra M;
McCarron, Edward C.
Published: 2018Citation: Journal of the National Cancer Institute. 110(2), 2018 Feb 01.Institution: Washington Cancer Institute; MedStar Franklin Square Medical Center.Publication: Journal Article.Article type: Journal Article.Full author list: Bandos H; Melnikow J; Rivera DR; Swain SM; Sturtz K; Fehrenbacher L; Wade JL 3rd; Brufsky AM; Julian TB; Margolese RG; McCarron EC; Ganz PA.UI/PMID: 28954297.Digital Object Identifier: https://dx.doi.org/10.1093/jnci/djx162 (Click here)
|
|
|
17.
|
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
by Swain, Sandra M.
Published: 2016Citation: Annals of Surgical Oncology. 24(7):1853-1860, 2017 Jul.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Bear HD; Tang G; Rastogi P; Geyer CE Jr; Zoon CK; Kidwell KM; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 27864694.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1245/s10434-016-5662-9 (Click here)
|
|
|
18.
|
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial
by Swain, Sandra M.
Published: 2017Citation: JAMA Oncology. 3(3):335-341, 2017 Mar 01.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial.Full author list: Gavin PG; Song N; Kim SR; Lipchik C; Johnson NL; Bandos H; Finnigan M; Rastogi P; Fehrenbacher L; Mamounas EP; Swain SM; Wickerham DL; Geyer CE Jr; Jeong JH; Costantino JP; Wolmark N; Paik S; Pogue-Geile KL.UI/PMID: 27812689.Digital Object Identifier: https://dx.doi.org/10.1001/jamaoncol.2016.4884 (Click here)
|
|
|
19.
|
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens
by Swain, Sandra M.
Published: 2017Citation: Clinical Breast Cancer. 17(1):76-78, 2017 Feb.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Gao JJ; Tan M; Pohlmann PR; Swain SM.UI/PMID: 27692565.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.clbc.2016.08.005 (Click here)
|
|
|
20.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
by Swain, Sandra M.
Published: 2017Citation: Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Smith JW 2nd; Buyse ME; Rastogi P; Geyer CE Jr; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N.UI/PMID: 27693116.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.clbc.2016.07.008 (Click here)
|
|
|
21.
|
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function
by Lynce, Filipa;
Barac, Ana;
Asch, Federico M;
Swain, Sandra M.
Published: 2017Citation: Oncologist. 22(5):518-525, 2017 May.Institution: Washington Cancer Institute; MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM.UI/PMID: 28314836.Digital Object Identifier: https://dx.doi.org/10.1634/theoncologist.2016-0412 (Click here)
|
|
|
22.
|
Pertuzumab for the treatment of breast cancer: a safety review. [Review]
by Swain, Sandra M.
Published: 2016Citation: Expert Opinion on Drug Safety. 15(6):853-63, 2016 Jun.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Review.Full author list: Gao J; Swain SM.UI/PMID: 26982349.Digital Object Identifier: https://dx.doi.org/10.1517/14740338.2016.1167185 (Click here)
|
|
|
23.
|
Cardiovascular Disease After Aromatase Inhibitor Use
by Barac, Ana.
Published: 2016Citation: JAMA Oncology. 2(12):1590-1597, 2016 Dec 01.Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT.UI/PMID: 27100398.Digital Object Identifier: https://dx.doi.org/10.1001/jamaoncol.2016.0429 (Click here)
|
|
|
24.
|
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl
by Swain, Sandra M.
Published: 2016Citation: Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S.UI/PMID: 26759246.
|
|
|
25.
|
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines
by Barac, Ana;
Lynce, Filipa;
Mete, Mihriye;
Shara, Nawar M;
Asch, Federico M;
Wray, Lynette;
Herbolsheimer, Pia M;
Nunes, Raquel;
Swain, Sandra M.
Published: 2016Citation: Breast Cancer Research & Treatment. 155(2):285-93, 2016 Jan..Institution: MedStar Washington Hospital Center; Washington Cancer Institute; MedStar Health Research Institute; MedStar Health Research Institute; MedStar Washington Hospital Center; MedStar Health Research Institute; Washington Cancer Instituteia; Washington Cancer Institute A; Washington Cancer Institute.Department: MedStar Heart Institute; MedStar Heart Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Barac A; Lynce F; Smith KL; Mete M; Shara NM; Asch FM; Nardacci MP; Wray L; Herbolsheimer P; Nunes RA; Swain SM; Warren R; Peshkin BN; Isaacs C.UI/PMID: 26749359.
|
|
|
26.
|
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38
by Swain, Sandra M.
Published: 2016Citation: Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Multicenter Study; Randomized Controlled Trial.Full author list: Cecchini RS; Swain SM; Costantino JP; Rastogi P; Jeong JH; Anderson SJ; Tang G; Geyer CE Jr; Lembersky BC; Romond EH; Paterson AH; Wolmark N.UI/PMID: 26545405.Digital Object Identifier: http://dx.doi.org/10.1158/1055-9965.EPI-15-0334-T (Click here)
|
|
|
27.
|
Acquired von Willebrand disease and multiple myeloma: a case report of a breast cancer survivor
by Jin, Ning;
Salahuddin, Farah F;
Nesbitt, John A.
Edition: Blood Coagulation & Fibrinolysis. 25(8):890-3, 2014 Dec.Published: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis ; 2014Institution: MedStar Union Memorial Hospital.Department: Medicine.Publication: Journal Article.Article type: Case Reports; Journal Article.UI/PMID: 24911454.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1097/MBC.0000000000000149 (Click here)
|
|
|
28.
|
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
by Swain, Sandra M.
Citation: Lancet Oncology. 16(9):1037-48, 2015 Sep..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Bear HD; Tang G; Rastogi P; Geyer CE Jr; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 26272770.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(15)00041-8 (Click here)
|
|
|
29.
|
Reply to a. Avan et Al
by Swain, Sandra M.
Citation: Journal of Clinical Oncology. 33(15):1712, 2015 May 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Letter.Full author list: Baselga J; Clark E; Kiermaier A; Swain S.UI/PMID: 25870094.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2015.60.8398 (Click here)
|
|
|
30.
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial
by Swain, Sandra M.
Citation: Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Pogue-Geile KL; Song N; Jeong JH; Gavin PG; Kim SR; Blackmon NL; Finnigan M; Rastogi P; Fehrenbacher L; Mamounas EP; Swain SM; Wickerham DL; Geyer CE Jr; Costantino JP; Wolmark N; Paik S.UI/PMID: 25559813.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2014.56.2439 (Click here)
|
|
|
31.
|
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. []
by Swain, Sandra M.
Citation: Breast Cancer Research & Treatment. 149(1):163-9, 2015 Jan..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't.Full author list: Tan AR; Johannes H; Rastogi P; Jacobs SA; Robidoux A; Flynn PJ; Thirlwell MP; Fehrenbacher L; Stella PJ; Goel R; Julian TB; Provencher L; Bury MJ; Bhatt K; Geyer CE Jr; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 25542269.Digital Object Identifier: http://dx.doi.org/10.1007/s10549-014-3221-2 (Click here)
|
|
|
32.
|
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831
by Swain, Sandra M.
Citation: Journal of Clinical Oncology. 32(33):3744-52, 2014 Nov 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE Jr; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N.UI/PMID: 25332249.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2014.55.5730 (Click here)
|
|
|
33.
|
Treatment of HER2-positive metastatic breast cancer
by Swain, Sandra M.
Citation: New England Journal of Medicine. 372(20):1964-5, 2015 May 14..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Letter.Full author list: Swain SM; Clark E; Baselga J.UI/PMID: 25970056.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1056/NEJMc1503446 (Click here)
|
|
|
34.
|
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA
by Swain, Sandra M.
Citation: Oncologist. 19(7):693-701, 2014 Jul..Institution: Washington Cancer Institute.Publication: Journal Article.Full author list: Swain SM; Im YH; Im SA; Chan V; Miles D; Knott A; Clark E; Ross G; Baselga J.UI/PMID: 24869931.Digital Object Identifier: http://dx.doi.org/10.1634/theoncologist.2014-0033 (Click here)
|
|
|
35.
|
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
by Swain, Sandra M.
Citation: BMC Cancer. 14:307, 2014..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't.Full author list: Tripathy D; Rugo HS; Kaufman PA; Swain S; O'Shaughnessy J; Jahanzeb M; Mason G; Beattie M; Yoo B; Lai C; Masaquel A; Hurvitz S.UI/PMID: 24885258.Digital Object Identifier: http://dx.doi.org/10.1186/1471-2407-14-307 (Click here)
|
|
|
36.
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
by Swain, Sandra M.
Citation: New England Journal of Medicine. 372(8):724-34, 2015 Feb 19..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortes J; CLEOPATRA Study Group.UI/PMID: 25693012.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1056/NEJMoa1413513 (Click here)
|
|
|
37.
|
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer
by Swain, Sandra M.
Citation: Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Baselga J; Cortes J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM.UI/PMID: 25332247.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2013.54.5384 (Click here)
|
|
|
38.
|
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
by Swain, Sandra M.
Citation: Annals of Oncology. 25(6):1116-21, 2014 Jun..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Swain SM; Baselga J; Miles D; Im YH; Quah C; Lee LF; Cortes J.UI/PMID: 24685829.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1093/annonc/mdu133 (Click here)
|
|
|
39.
|
Pertuzumab for the treatment of breast cancer. [Review]
by Swain, Sandra M;
Lynce, Filipa.
Citation: Cancer Investigation. 32(8):430-8, 2014 Oct..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't; Review.Full author list: Lynce F; Swain SM.UI/PMID: 24921704.Digital Object Identifier: http://dx.doi.org/10.3109/07357907.2014.922570 (Click here)
|
|
|
40.
|
Pertuzumab: increasing the options
by Nunes, Raquel;
Swain, Sandra M.
Citation: Oncology (Williston Park). 28(3):199, 204, 210, 2014 Mar..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Journal Article; Research Support, Non-U.S. Gov't.Full author list: Nunes R; Swain SM.UI/PMID: 24855727.Online Access: Click here to access online
|
|
|
41.
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
by Swain, Sandra M.
Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Miles D; Baselga J; Amadori D; Sunpaweravong P; Semiglazov V; Knott A; Clark E; Ross G; Swain SM.UI/PMID: 24129974.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1007/s10549-013-2710-z (Click here)
|
|
|
42.
|
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer
by Swain, Sandra M.
Citation: Annals of Oncology. 24(10):2630-5, 2013 Oct..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Cortes J; Baselga J; Im YH; Im SA; Pivot X; Ross G; Clark E; Knott A; Swain SM.UI/PMID: 23868905.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1093/annonc/mdt274 (Click here)
|
|
|
43.
|
Reply to E.J. Moylan et al
by Swain, Sandra M.
Citation: Journal of Clinical Oncology. 32(6):606-7, 2014 Feb 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Letter.Full author list: Swain SM; Tang G; Geyer CE Jr.UI/PMID: 24419136.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2013.53.8744 (Click here)
|
|
|
44.
|
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel
by Swain, Sandra M.
Citation: Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't.Full author list: Cortes J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J.UI/PMID: 23969513.Digital Object Identifier: http://dx.doi.org/10.1097/CAD.0000000000000016 (Click here)
|
|
|
45.
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31
by Swain, Sandra M.
Citation: Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Pogue-Geile KL; Kim C; Jeong JH; Tanaka N; Bandos H; Gavin PG; Fumagalli D; Goldstein LC; Sneige N; Burandt E; Taniyama Y; Bohn OL; Lee A; Kim SI; Reilly ML; Remillard MY; Blackmon NL; Kim SR; Horne ZD; Rastogi P; Fehrenbacher L; Romond EH; Swain SM; Mamounas EP; Wickerham DL; Geyer CE Jr; Costantino JP; Wolmark N; Paik S.UI/PMID: 24262440.Digital Object Identifier: http://dx.doi.org/10.1093/jnci/djt321 (Click here)
|
|
|
46.
|
Adjuvant trastuzumab: does time really matter?
by Swain, Sandra M.
Citation: Oncologist. 18(5):490-2, 2013..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Swain SM.UI/PMID: 23624497.Digital Object Identifier: http://dx.doi.org/10.1634/theoncologist.2013-0094 (Click here)
|
|
|
47.
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
by Swain, Sandra M.
Citation: Lancet Oncology. 14(12):1183-92, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Robidoux A; Tang G; Rastogi P; Geyer CE Jr; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 24095300.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(13)70411-X (Click here)
|
|
|
48.
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
by Swain, Sandra M.
Citation: Journal of Clinical Oncology. 31(26):3197-204, 2013 Sep 10..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural.Full author list: Swain SM; Tang G; Geyer CE Jr; Rastogi P; Atkins JN; Donnellan PP; Fehrenbacher L; Azar CA; Robidoux A; Polikoff JA; Brufsky AM; Biggs DD; Levine EA; Zapas JL; Provencher L; Northfelt DW; Paik S; Costantino JP; Mamounas EP; Wolmark N.UI/PMID: 23940225.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2012.48.1275 (Click here)
|
|
|
49.
|
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study
by Swain, Sandra M.
Citation: Oncologist. 18(3):257-64, 2013..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Swain SM; Ewer MS; Cortes J; Amadori D; Miles D; Knott A; Clark E; Benyunes MC; Ross G; Baselga J.UI/PMID: 23475636.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1634/theoncologist.2012-0448 (Click here)
|
|
|
50.
|
Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. [Review]
by Swain, Sandra M.
Citation: Expert Opinion on Biological Therapy. 13(5):779-90, 2013 May..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't; Review.Full author list: O'Sullivan CC; Swain SM.UI/PMID: 23530718.Digital Object Identifier: http://dx.doi.org/10.1517/14712598.2013.783007 (Click here)
|
|
|
51.
|
Avastin withdrawal symptoms
by Lynce, Filipa;
Swain, Sandra M.
Citation: Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Editorial; Research Support, Non-U.S. Gov't.Full author list: Lynce F; Swain SM.UI/PMID: 22263961.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1517/14656566.2012.652088 (Click here)
|
|
|
52.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
by Swain, Sandra M.
Published: 2013Citation: Lancet Oncology. 14(6):461-71, 2013 May..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Baselga J; Benyunes MC; Campone M; Ciruelos E; Clark E; Cortes J; Ferrero JM; Kim SB; Knott A; Ro J; Ross G; Schneeweiss A; Semiglazov V; Swain SM.UI/PMID: 23602601.Online Access: Click here to access online Digital Object Identifier: (Click here)
|
|
|
53.
|
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
by Swain, Sandra M.
Citation: Lancet. 379(9814):432-44, 2012 Feb 4..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't.Full author list: Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Peto R; Davies C; Godwin J; Gray R; Pan HC; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang YC; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K.UI/PMID: 22152853.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S0140-6736(11)61625-5 (Click here)
|
|
|
54.
|
Pazopanib for the treatment of breast cancer. [Review]
by Swain, Sandra M.
Citation: Expert Opinion on Investigational Drugs. 21(2):217-25, 2012 Feb..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, N.I.H., Extramural; Review.Full author list: Amiri-Kordestani L; Tan AR; Swain SM.UI/PMID: 22233389.Digital Object Identifier: http://dx.doi.org/10.1517/13543784.2012.652304 (Click here)
|
|
|
55.
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24
by Swain, Sandra M.
Citation: Journal of Clinical Oncology. 30(12):1268-73, 2012 Apr 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE Jr; Costantino JP; Land SR; Wolmark N.UI/PMID: 22393101.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2010.34.0141 (Click here)
|
|
|
56.
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
by Swain, Sandra M.
Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S..Full author list: Bear HD; Tang G; Rastogi P; Geyer CE Jr; Robidoux A; Atkins JN; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 22276821.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1056/NEJMoa1111097 (Click here)
|
|
|
57.
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
by Swain, Sandra M.
Citation: Lancet Oncology. 13(7):734-42, 2012 Jul..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Paterson AH; Anderson SJ; Lembersky BC; Fehrenbacher L; Falkson CI; King KM; Weir LM; Brufsky AM; Dakhil S; Lad T; Baez-Diaz L; Gralow JR; Robidoux A; Perez EA; Zheng P; Geyer CE Jr; Swain SM; Costantino JP; Mamounas EP; Wolmark N.UI/PMID: 22704583.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(12)70226-7 (Click here)
|
